Financial Overview

Financials

Sequent Scientific Limited is India’s leading animal health company.

Quarterly Financial - Results

The SeQuent financial reports

Select Year and Quater

Call transcript

  • Q2
  • 2024-2025

Newspaper

  • Q2
  • 2024-2025

Financial

  • Q2
  • 2024-2025

Investor presentation

  • Q2
  • 2024-2025

Investor call recording

  • Q2
  • 2024-2025

Call Transcript

  • Q1
  • 2024-2025

Earnings Call Audio Recording

  • Q1
  • 2024-2025

Earning Presentation

  • Q1
  • 2024-2025

Signed Financials

  • Q1
  • 2024-2025

Signed Financials

  • Q1
  • 2023-2024

Earning Presentation

  • Q1
  • 2023-2024

Earnings Call Audio Recording

  • Q1
  • 2023-2024

Call Transcript

  • Q1
  • 2023-2024

Signed Financials

  • Q2
  • 2023-2024

Earning Presentation

  • Q2
  • 2023-2024

Earnings Call Audio Recording

  • Q2
  • 2023-2024

Call Transcript

  • Q2
  • 2023-2024

Signed Financials

  • Q3
  • 2023-2024

Earning Presentation

  • Q3
  • 2023-2024

Earnings Call Audio Recording

  • Q3
  • 2023-2024

Call Transcript

  • Q3
  • 2023-2024

Signed Financials

  • Q4
  • 2023-2024

Earning Presentation

  • Q4
  • 2023-2024

Earnings Call Audio Recording

  • Q4
  • 2023-2024

Call Transcript

  • Q4
  • 2023-2024

Signed Financials

  • Q1
  • 2022-2023

Earning Presentation

  • Q1
  • 2022-2023

Earnings Call Audio Recording

  • Q1
  • 2022-2023

Call Transcript

  • Q1
  • 2022-2023

Signed Financials

  • Q2
  • 2022-2023

Earning Presentation

  • Q2
  • 2022-2023

Earnings Call Audio Recording

  • Q2
  • 2022-2023

Call Transcript

  • Q2
  • 2022-2023

Signed Financials

  • Q3
  • 2022-2023

Earning Presentation

  • Q3
  • 2022-2023

Earnings Call Audio Recording

  • Q3
  • 2022-2023

Call Transcript

  • Q3
  • 2022-2023

Signed Financials

  • Q4
  • 2022-2023

Earning Presentation

  • Q4
  • 2022-2023

Earnings Call Audio Recording

  • Q4
  • 2022-2023

Call Transcript

  • Q4
  • 2022-2023

Signed Financials

  • Q1
  • 2021-2022

Earning Presentation

  • Q1
  • 2021-2022

Call Transcript

  • Q1
  • 2021-2022

Signed Financials

  • Q2
  • 2021-2022

Earning Presentation

  • Q2
  • 2021-2022

Call Transcript

  • Q2
  • 2021-2022

Signed Financials

  • Q3
  • 2021-2022

Earning Presentation

  • Q3
  • 2021-2022

Call Transcript

  • Q3
  • 2021-2022

Signed Financials

  • Q4
  • 2021-2022

Earning Presentation

  • Q4
  • 2021-2022

Earnings Call Audio Recording

  • Q4
  • 2021-2022

Call Transcript

  • Q4
  • 2021-2022

Signed Financials

  • Q1
  • 2020-2021

Earning Presentation

  • Q1
  • 2020-2021

Call Transcript

  • Q1
  • 2020-2021

Signed Financials

  • Q2
  • 2020-2021

Earning Presentation

  • Q2
  • 2020-2021

Call Transcript

  • Q2
  • 2020-2021

Signed Financials

  • Q3
  • 2020-2021

Earning Presentation

  • Q3
  • 2020-2021

Call Transcript

  • Q3
  • 2020-2021

Signed Financials

  • Q4
  • 2020-2021

Earning Presentation

  • Q4
  • 2020-2021

Call Transcript

  • Q4
  • 2020-2021

Signed Financials

  • Q1
  • 2019-2020

Earning Presentation

  • Q1
  • 2019-2020

Call Transcript

  • Q1
  • 2019-2020

Signed Financials

  • Q2
  • 2019-2020

Earning Presentation

  • Q2
  • 2019-2020

Call Transcript

  • Q2
  • 2019-2020

Signed Financials

  • Q3
  • 2019-2020

Earning Presentation

  • Q3
  • 2019-2020

Call Transcript

  • Q3
  • 2019-2020

Signed Financials

  • Q4
  • 2019-2020

Earning Presentation

  • Q4
  • 2019-2020

Call Transcript

  • Q4
  • 2019-2020

Signed Financials

  • Q1
  • 2018-2019

Earning Presentation

  • Q1
  • 2018-2019

Call Transcript

  • Q1
  • 2018-2019

Signed Financials

  • Q2
  • 2018-2019

Earning Presentation

  • Q2
  • 2018-2019

Call Transcript

  • Q2
  • 2018-2019

Signed Financials

  • Q3
  • 2018-2019

Earning Presentation

  • Q3
  • 2018-2019

Call Transcript

  • Q3
  • 2018-2019

Investors Presentation Nov 2019

  • Q3
  • 2018-2019

Signed Financials

  • Q4
  • 2018-2019

Earning Presentation

  • Q4
  • 2018-2019

Call Transcript

  • Q4
  • 2018-2019

Quarter ended 1

  • Q1
  • 2017-2018

Quarter ended 2

  • Q2
  • 2017-2018

Quarter ended 3

  • Q3
  • 2017-2018

Quarter ended 4

  • Q4
  • 2017-2018

Quarter ended 1

  • Q1
  • 2016-2017

Quarter ended 2

  • Q2
  • 2016-2017

Quarter ended 3

  • Q3
  • 2016-2017

Quarter ended 4

  • Q4
  • 2016-2017

Quarter ended 1

  • Q1
  • 2015-2016

Share holding pattern

The SeQuent financial reports

Select Year and Quater

Shareholding pattern – Sep 30, 2024

  • Q3
  • 2024-2025

Quarter ended 1

  • Q1
  • 2024-2025

Quarter ended 1

  • Q1
  • 2023-2024

Quarter ended 2

  • Q2
  • 2023-2024

Quarter ended 3

  • Q3
  • 2023-2024

Quarter ended 4

  • Q4
  • 2023-2024

Quarter ended 1

  • Q1
  • 2022-2023

Quarter ended 2

  • Q2
  • 2022-2023

Quarter ended 3

  • Q3
  • 2022-2023

Quarter ended 4

  • Q4
  • 2022-2023

Quarter ended 1

  • Q1
  • 2021-2022

Quarter ended 2

  • Q2
  • 2021-2022

Quarter ended 3

  • Q3
  • 2021-2022

Quarter ended 4

  • Q4
  • 2021-2022

Quarter ended 1

  • Q1
  • 2020-2021

Quarter ended 2

  • Q2
  • 2020-2021

Quarter ended 3

  • Q3
  • 2020-2021

Quarter ended 4

  • Q4
  • 2020-2021

Quarter ended 1

  • Q1
  • 2019-2020

Quarter ended 2

  • Q2
  • 2019-2020

Quarter ended 3

  • Q3
  • 2019-2020

Quarter ended 4

  • Q4
  • 2019-2020

Quarter ended 1

  • Q1
  • 2018-2019

Quarter ended 2

  • Q2
  • 2018-2019

Quarter ended 3

  • Q3
  • 2018-2019

Quarter ended 4

  • Q4
  • 2018-2019

Quarter ended 1

  • Q1
  • 2017-2018

Quarter ended 2

  • Q2
  • 2017-2018

Quarter ended 3

  • Q3
  • 2017-2018

Quarter ended 4

  • Q4
  • 2017-2018

Quarter ended 1

  • Q1
  • 2016-2017

Quarter ended 2

  • Q2
  • 2016-2017

Quarter ended 3

  • Q3
  • 2016-2017

Quarter ended 4

  • Q4
  • 2016-2017

Quarter ended 1

  • Q1
  • 2015-2016

Quarter ended 2

  • Q2
  • 2015-2016

Quarter ended 3

  • Q3
  • 2015-2016

Quarter ended 4

  • Q4
  • 2015-2016

Quarter ended 1

  • Q1
  • 2014-2015

Quarter ended 2

  • Q2
  • 2014-2015

Quarter ended 3

  • Q3
  • 2014-2015

Quarter ended 4

  • Q4
  • 2014-2015

Quarter ended 1

  • Q1
  • 2013-2014

Quarter ended 2

  • Q2
  • 2013-2014

Quarter ended 3

  • Q3
  • 2013-2014

Quarter ended 4

  • Q4
  • 2013-2014

Quarter ended 1

  • Q1
  • 2012-2013

Quarter ended 2

  • Q2
  • 2012-2013

Quarter ended 3

  • Q3
  • 2012-2013

Quarter ended 4

  • Q4
  • 2012-2013

Quarter ended 1

  • Q1
  • 2011-2012

Quarter ended 2

  • Q2
  • 2011-2012

Quarter ended 3

  • Q3
  • 2011-2012

Quarter ended 4

  • Q4
  • 2011-2012

Press Release

Select Year

Sequent Scientific Limited Receives Prequalification Approval from World Health Organization (WHO) for Albendazole API

  • 2024-2025

SeQuent Scientific and Viyash Lifesciences Announce Strategic Merger to Create a Global Animal Health Leader with End-to-End Integrated Capabilities

  • 2024-2025

SeQuent Scientific Appoints Pharmaceutical Industry Leader Rajaram Narayanan as Managing Director and CEO

  • 2021-2022

Acquisition of Nourrie

  • 2021-2022

SeQuent announced EUGMP approval for its tablets dosage form in Turkey

  • 2021-2022

SeQuent Scientific Ltd Press Release Q4 FY21

  • 2020-2021

SeQuent received CEP approval for Diclazuril API

  • 2020-2021

Corporate update – December 22, 2020

  • 2020-2021

Investors/analysts Conference Call – Corporate Update – December 22, 2020

  • 2020-2021

SeQuent announced launch of Citramox® LA in EU

  • 2020-2021

Launch of inhouse developed Halofusol® in EU

  • 2020-2021

SeQuent Scientific Ltd PR Q2 FY21

  • 2020-2021

SeQuent Announces Reconstitution of Board

  • 2020-2021

SeQuent Scientific provides Covid-19 and Business Update

  • 2020-2021

Sequent Scientific announces WHO-Geneva approval for its Vizag facility

  • 2019-2020

Sequent Scientific announces addition of new state-of-art Animal Health R&D Centre at Mumbai

  • 2019-2020

SeQuent Scientific receives EIR from US FDA for its Analytical Laboratory at Bengaluru

  • 2019-2020

Earnings Transcript May 14, 2019

  • 2019-2020

SeQuent Scientific Announces Q4 and Annual FY19 Financial

  • 2019-2020

Change in Credit Rating

  • 2019-2020

Earning Transcripts February 1, 2019

  • 2018-2019

Sequent financials press release SeQuent Scientific Announces Q3 FY19 Financial Results

  • 2018-2019

SeQuent Scientific Ltd. receives EIR from USDFA for its Analytical Lab at Mangalore

  • 2018-2019

Earning Transcripts November 2, 2018

  • 2018-2019

SeQuent Scientific Announces Q2 FY19 Financial Results

  • 2018-2019

Earning Transcripts August 10 2018

  • 2018-2019

SeQuent Scientific Announces Q1 FY19 Financial Results

  • 2018-2019

Sequent Scientific Earnings Transcript Q4 FY 18 Financial Results

  • 2017-2018

SeQuent Scientific Announces Q4 FY18 Financial Results alongwith Investors Presentation

  • 2017-2018

SeQuent Scientific Announces Q3 FY18 Financial Results

  • 2017-2018

Sequent Scientific Announces Q2 FY 18 Financial Results

  • 2017-2018

Sequent Scientific Announces Q1 FY 18 Financial Results

  • 2017-2018

SeQuent Scientific announces FY17 Financial Results

  • 2017-2018

Establishment Inspection Report – Visakhapatnam (Vizag) Plant

  • 2017-2018

SeQuent Scientific announces Q3FY17 Financial Results

  • 2016-2017

SeQuent Scientific to become a pur-play Animal Health Company

  • 2016-2017

SeQuent Scientific announces Q2FY17 Financial Results

  • 2016-2017

SeQuent Scientific announces Q1FY17 Financial Results

  • 2016-2017

Alivira completes the acquisition of 70% stake in Interchange, Brazil

  • 2016-2017

Alivira to acquire majority stake in Karizoo Group Spain

  • 2016-2017

SeQuent Scientific announces FY16 Financial Results

  • 2016-2017

Alivira to acquire controlling interest in Interchange Brazil

  • 2016-2017

SeQuent Scientific Mahad Facility Receives Environment Clearance from SEIAA

  • 2015-2016

SeQuent Scientific announces Q3FY16 Financial Results

  • 2015-2016

Sequent Scientific to acquire controlling stake in Indo Phyto Chemicals Forays into steroids and hormones for Female Healthcare

  • 2015-2016

Alivira forays into European Veterinary Market

  • 2015-2016

Alivira to acquire Topkim, Turkey Will make Alivira the largest Animal Health Company of Turkey

  • 2015-2016

SeQuent receives Establishment Inspection Report from US FDA for its API Drug Manufacturing Facility at Mangalore

  • 2015-2016

SeQuent Scientific announces Q2FY16 Financial Results

  • 2015-2016

SeQuent Scientific completes acquisition of Animal Health business of Lyka Exports

  • 2015-2016

SeQuent Scientific to acquire Animal Health business of Lyka Exports

  • 2015-2016

SeQuent Scientific announces Q1FY16 Financial Results

  • 2015-2016

SeQuent Scientific announces Q1FY16 Financial Results

  • 2014-2015

SeQuent Scientific completes fund raise of INR 4,000 mn through Qualified Institutional Placement

  • 2014-2015

SeQuent Scientific announces Q4 – FY 2014-15 Results

  • 2014-2015

SeQuent Scientific announces Q3 – FY 2014-15 Results

  • 2014-2015

SeQuent Scientific announces Q2 – FY 2014-15 Results

  • 2014-2015

SeQuent Scientific announces Q1 – FY 2014-15 Results

  • 2014-2015

Sequent Scientific announces licensing agreement with Gilead Sciences, Inc for new Hepatitis C drug

  • 2013-2014

Alivira Animal Health to acquire majority stake in Provet Veterinary Products AS of Turkey

  • 2013-2014

SeQuent Scientific Limited announces completion of Sale of Specialty Chemicals division to Songwon Industrial Group

  • 2013-2014

SeQuent Scientific announces FY 2013-14 Results

  • 2013-2014

SeQuent Scientific to acquire the business of Arvee Synthesis

  • 2013-2014

Songwon Industrial Group to acquire Specialty Chemicals Division of SeQuent Scientific Limited

  • 2013-2014

SeQuent Scientific to acquire the business of Arvee Synthesis Acquisition to provide impetus to Human API business

  • 2013-2014

Songwon Industrial Group to acquire Specialty Chemicals Division of SeQuent Scientific Limited

  • 2013-2014

Sequent Scientific Ltd & Shasun Pharmaceuticals Ltd Announce Joint Venture To Create Leading Animal Health Company

  • 2012-2013

Sequent Scientific Receives Us Fda Approval For Its Api Drug Manufacturing Facility At Mangalore

  • 2012-2013

Presentations

Annual Reports

Select Year

SeQuent Scientific Limited (BSE: 512529, NSE: SEQUENT), headquartered in India, operates in Animal Health market with a global footprint. SeQuent has seven manufacturing facilities based in India, Spain, Brazil and Turkey with approvals from international regulatory bodies, including USFDA, EUGMP, WHO, TGA, etc. SeQuent currently produces APIs and Animal health formulations in over 100 countries and has more than 1,500 employees.

Investor Relation

Company

Privacy & Policy

© 2024 Sequent. All rights reserved

Crafted by : Version-Next